Established in Visp in 1897, Lonza has developed one of the world’s largest integrated biomanufacturing sites. Today, the Valais site combines large-scale biologics production, advanced modalities and chemical manufacturing within a global CDMO network serving pharmaceutical and biotech companies worldwide.

The Visp site is Lonza’s largest production hub globally and a central pillar of its drug substance activities.

The platform integrates mammalian cell culture, microbial fermentation, highly potent API manufacturing and bioconjugation technologies. Over time, Visp has evolved from a traditional chemical production site into a multi-modality manufacturing campus.

The site supports customers from clinical development to commercial supply, within long-term manufacturing partnerships.

Biologics and advanced therapies

Visp is a major center for biologics manufacturing, including monoclonal antibodies and recombinant proteins produced in large-scale bioreactors.

The site also hosts capabilities in antibody-drug conjugates (ADCs), combining biologics and highly potent payloads within controlled environments.

Lonza has invested significantly in expanding biomanufacturing capacity in Visp over the past decade, reinforcing its position in advanced therapeutics and complex modalities.

Chemical manufacturing and HPAPI expertise

Alongside biologics, Visp maintains strong capabilities in chemical synthesis and highly potent APIs.

Dedicated infrastructure supports containment, process control and industrial scale for complex and potent compounds.

This combination of chemical and biological manufacturing within the same industrial campus remains a distinctive feature of the site.

An anchor within a global CDMO group

Lonza operates globally as a development and manufacturing partner for the pharmaceutical, biotech and specialty ingredients markets.

At Group level (FY 2025), Lonza reports:

• CHF 6.7 billion in sales

• More than 17,000 employees worldwide

• A global network spanning Europe, North America and Asia

Within this structure, Visp plays a central role in large-scale drug substance manufacturing and advanced therapy production.